Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Difference between revisions of "Asping 2017 Eur J Clin Pharmacol"

From Bioblast
(Created page with "{{Publication |title=Asping M, Stride N, Søgaard D, Dohlmann TL, Helge JW, Dela F, Larsen S (2017) The effects of 2 weeks of statin treatment on mitochondrial respiratory cap...")
 
 
(2 intermediate revisions by one other user not shown)
Line 16: Line 16:
|keywords=Human, Mitochondrial function, Side effects, Skeletal muscle, Statins
|keywords=Human, Mitochondrial function, Side effects, Skeletal muscle, Statins
|editor=[[Kandolf G]]
|editor=[[Kandolf G]]
|mipnetlab=DK Copenhagen Dela F
|mipnetlab=DK Copenhagen Dela F, DK Copenhagen Larsen S
}}
}}
{{Labeling
{{Labeling
Line 24: Line 24:
|couplingstates=LEAK, ET
|couplingstates=LEAK, ET
|pathways=F, N, S, CIV, NS, ROX
|pathways=F, N, S, CIV, NS, ROX
|instruments=O2k-FluoRespirometer
|instruments=Oxygraph-2k
|additional=Labels, 2017-11
|additional=Labels, 2017-11, BMI, VO2max
}}
}}

Latest revision as of 14:48, 5 March 2019

Publications in the MiPMap
Asping M, Stride N, Søgaard D, Dohlmann TL, Helge JW, Dela F, Larsen S (2017) The effects of 2 weeks of statin treatment on mitochondrial respiratory capacity in middle-aged males: the LIFESTAT study. Eur J Clin Pharmacol 73:679-87.

» PMID: 28246888

Asping M, Stride N, Soegaard D, Dohlmann TL, Helge JW, Dela F, Larsen S (2017) Eur J Clin Pharmacol

Abstract: Statins are used to lower cholesterol in plasma and are one of the most used drugs in the world. Many statin users experience muscle pain, but the mechanisms are unknown at the moment. Many studies have hypothesized that mitochondrial function could be involved in these side effects.

The aim of the study was to investigate mitochondrial function after 2 weeks of treatment with simvastatin (S; n = 10) or pravastatin (P; n = 10) in healthy middle-aged participants.

Mitochondrial respiratory capacity and substrate sensitivity were measured in permeabilized muscle fibers by high-resolution respirometry. Mitochondrial content (citrate synthase (CS) activity), antioxidant content, as well as coenzyme Q10 concentration (Q10) were determined. Fasting plasma glucose and insulin concentrations were measured, and whole body maximal oxygen uptake (VO2max) was determined.

No differences were seen in mitochondrial respiratory capacity although a tendency was observed for a reduction when complex IV respiration was analyzed in both S (229 (169; 289 (95% confidence interval)) vs. 179 (146; 211) pmol/s/mg, respectively; P = 0.062) and P (214 (143; 285) vs. 162 (104; 220) pmol/s/mg, respectively; P = 0.053) after treatment. A tendency (1.64 (1.28; 2.00) vs. 1.28 (0.99; 1.58) mM, respectively; P = 0.092) for an increased mitochondrial substrate sensitivity (complex I-linked substrate; glutamate) was seen only in S after treatment. No differences were seen in Q10, CS activity, or antioxidant content after treatment. Fasting glucose and insulin as well as VO2max were not changed after treatment.

Two weeks of statin (S or P) treatment have no major effect on mitochondrial function. The tendency for an increased mitochondrial substrate sensitivity after simvastatin treatment could be an early indication of the negative effects linked to statin treatment. Keywords: Human, Mitochondrial function, Side effects, Skeletal muscle, Statins Bioblast editor: Kandolf G O2k-Network Lab: DK Copenhagen Dela F, DK Copenhagen Larsen S


Labels: MiParea: Respiration, mt-Medicine, Pharmacology;toxicology 


Organism: Human 

Preparation: Permeabilized tissue 


Coupling state: LEAK, ET  Pathway: F, N, S, CIV, NS, ROX  HRR: Oxygraph-2k 

Labels, 2017-11, BMI, VO2max